Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

This month, the U.S. Food and Drug Administration cleared two new oral antibiotics for use against gonorrhea: zoliflodacin ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

An American Heart Association presidential advisory in 2023 introduced a new term: cardiovascular-kidney-metabolic syndrome.

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

Advances delivered what may feel like medical miracles, including the first bladder transplant, a lifesaving personalized ...

I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and ...

A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing ...

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the Phase IV ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.